Small bowel perforation secondary to metastatic lung cancer with emphasis on the administration of erlotinib: a case report
|Updated:2026-03-12
|
Small bowel perforation secondary to metastatic lung cancer with emphasis on the administration of erlotinib: a case report
Military Medical ResearchVol. 27, Issue 4, Pages: 244-248(2012)
Affiliations:
1. Department of Critical Care Medicine, Jinhua Municipal Central Hospital
2. Department of Respiratory Medicine, Jinhua Municipal Central Hospital
3. Department of Hepatobiliary Surgery, Jinhua Municipal Central Hospital
Author bio:
Funds:
DOI:
CLC:R734.2
Published:2012
Accepted:
Scan QR Code
[1]Zhang Zhongheng,Chen Huijun,Li Xuemin.Small bowel perforation secondary to metastatic lung cancer with emphasis on the administration of erlotinib: a case report[J].Journal of Medical Colleges of PLA,2012,27(04):244-248.
DOI:
[1]Zhang Zhongheng,Chen Huijun,Li Xuemin.Small bowel perforation secondary to metastatic lung cancer with emphasis on the administration of erlotinib: a case report[J].Journal of Medical Colleges of PLA,2012,27(04):244-248.DOI:
Small bowel perforation secondary to metastatic lung cancer with emphasis on the administration of erlotinib: a case report
摘要
Abstract
Small bowel metastasis from primary lung cancer is rare. Once occurs
the metastasis may cause life-threatening complications
such as bowel perforation
obstruction and bleeding. We reported an 83-year old man who presented with small bowel perforation secondary to metastatic lung cancer after being treated with erlotinib for 2 weeks. We propose that the use of erlotinib may be associated with the small bowel perforation and precautions should be taken by clinicians in initiating erlotinib for primary lung cancer when there is bowel metastasis.
关键词
Keywords
references
The trial reading is over, you can activate your VIP account to continue reading.